Predictive Oncology Faces Nasdaq Delisting Warning

TL;DR

Nasdaq's threatening to kick POAI off the exchange, company's fighting back.

AI Summary

Predictive Oncology Inc. received a notice on September 19, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Market. The company is currently evaluating the notice and its options, which may include appealing the determination or submitting a plan to regain compliance. Failure to regain compliance could result in the delisting of its common stock from Nasdaq.

Why It Matters

This filing signals a significant risk to investors as the company's stock could be delisted from Nasdaq, potentially impacting liquidity and valuation.

Risk Assessment

Risk Level: high — The company has received a notice of non-compliance with Nasdaq listing rules, putting its stock at risk of delisting.

Key Players & Entities

• Predictive Oncology Inc. (company) — Registrant
• Nasdaq Capital Market (company) — Exchange where stock is listed
• September 19, 2024 (date) — Date of notice

FAQ

Key Financial Figures

• $0.01 — ch registered Common stock, par value $0.01 per share POAI NASDAQ Capital Marke
• $1.00 — Company's common stock had closed below $1.00 per share for 30 consecutive business d

Filing Documents

• f8k_091924.htm (8-K) — 22KB
• 0001171843-24-005297.txt ( ) — 192KB
• poai-20240919_lab.xml (EX-101.LAB) — 33KB
• poai-20240919_pre.xml (EX-101.PRE) — 22KB
• poai-20240919.xsd (EX-101.SCH) — 3KB
• f8k_091924_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 19, 2024, the Company received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the bid price for the Company's common stock had closed below $1.00 per share for 30 consecutive business days, and that the Company is therefore not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The notification has no immediate effect on the listing of the Company's common stock. The Company has a period of 180 calendar days, or until March 18, 2025, to regain compliance with the Minimum Bid Price Requirement. If, at any time before March 18, 2025, the bid price of the Company's common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement. The letter also disclosed that in the event the Company does not regain compliance with the Minimum Bid Price Requirement by March 18, 2025, the Company may be eligible for additional time. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that its securities would be subject to delisting. In the event of such notific

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Predictive Oncology Inc. Date: September 20, 2024 By: /s/ Josh Blacher Name: Josh Blacher Title: Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR